Cloud-Clone launches CML ELISA kit for glycation research

Cloud-Clone Corp. has introduced a Carboxymethyl-Lysine ELISA kit aimed at researchers studying diabetes, vascular damage, ageing, neuroinflammation and dietary AGE exposure. The kit is designed to improve measurement of a hard-to-detect biomarker that is often obscured by protein binding, cross-reactivity and sample-matrix interference.

Why it matters: - Carboxymethyl-lysine, or CML, is a core biomarker for advanced glycation end-products linked to diabetes complications, cardiovascular injury, ageing and other chronic-disease mechanisms. - More reliable CML measurement can improve research on glycation stress, the AGE-RAGE inflammatory pathway and anti-glycation drug screening. - Better assay performance matters because many standard methods struggle with low free-analyte levels, cross-reactivity and complex biological samples.

What happened: - Cloud-Clone Corp. said it developed a Carboxymethyl-Lysine ELISA kit, Cat. No. CEB977Ge, for quantitative CML research. - The kit is positioned for use in endocrinology, cardiovascular science, ageing biology, neuroscience, orthopaedics and nutritional-toxicology studies. - The company said the assay is validated for human, rat, mouse and rabbit samples.

The details: - CML is described as the most abundant AGEs biomarker and a marker of protein damage linked to hyperglycaemia and biological ageing. - The release says CML forms through non-enzymatic glycation and lipid peroxidation pathways. - CML accumulates in tissues under sustained hyperglycaemia, redox imbalance and ageing, where it can modify proteins and contribute to fibrosis and loss of elasticity. - The release says CML also binds the RAGE receptor and activates NF-κB-driven inflammatory signaling. - The kit is designed to address four common measurement problems: poor release of protein-bound CML, cross-reactivity with carboxyethyl-lysine, matrix interference and artefacts created during sample handling. - Cloud-Clone says the kit uses highly selective monoclonal antibodies, a companion dissociation buffer, a competitive ELISA format and optimized sample-processing reagents. - The assay is described as compatible with serum, plasma, tissue homogenates and cell-culture supernatants. - The company says the workflow uses ready-to-use reagents and 96-well plates and can be completed in about three hours. - The kit is designed to cover low CML levels in mild glycation stress and higher levels in severe diabetic models without repeated serial dilution. - Cloud-Clone also says the product is built to reduce false positives, under-quantification and matrix-driven variability.

Between the lines: - The launch reflects a broader demand for practical research tools that can measure AGEs more consistently in large animal studies and translational workflows. - The release positions ELISA as the more scalable option for routine research, while noting that LC-MS/MS remains the specificity benchmark but is slower, costlier and lower-throughput. - The emphasis on dissociation and antibody selectivity signals that CML assay quality is still a technical bottleneck for many labs.

What's next: - Cloud-Clone says it will continue developing assay products targeting glycation-stress markers, metabolic small molecules and inflammatory biomarkers. - The company is pitching the CML kit for studies of diabetic complications, atherosclerosis, ageing, neuroinflammation, bone metabolism and dietary glycotoxin exposure. - Researchers using the kit are expected to apply it in animal-model validation, mechanistic studies and drug-screening work.

The bottom line: - Cloud-Clone is betting that a more selective, higher-throughput CML ELISA will make a difficult biomarker easier to use across chronic-disease research.